DK3860998T3 - Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet - Google Patents

Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet Download PDF

Info

Publication number
DK3860998T3
DK3860998T3 DK19791146.4T DK19791146T DK3860998T3 DK 3860998 T3 DK3860998 T3 DK 3860998T3 DK 19791146 T DK19791146 T DK 19791146T DK 3860998 T3 DK3860998 T3 DK 3860998T3
Authority
DK
Denmark
Prior art keywords
compositions
compounds
conditions associated
receptor activity
treating conditions
Prior art date
Application number
DK19791146.4T
Other languages
English (en)
Inventor
Haifeng Tang
Michael Hanson
Sarah Boyce
Zhe Nie
Original Assignee
Annapurna Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annapurna Bio Inc filed Critical Annapurna Bio Inc
Application granted granted Critical
Publication of DK3860998T3 publication Critical patent/DK3860998T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK19791146.4T 2018-10-05 2019-10-04 Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet DK3860998T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862742218P 2018-10-05 2018-10-05
PCT/US2019/054880 WO2020073011A1 (en) 2018-10-05 2019-10-04 Compounds and compositions for treating conditions associated with apj receptor activity

Publications (1)

Publication Number Publication Date
DK3860998T3 true DK3860998T3 (da) 2024-03-25

Family

ID=68296866

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19791146.4T DK3860998T3 (da) 2018-10-05 2019-10-04 Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet

Country Status (18)

Country Link
US (2) US11471455B2 (da)
EP (2) EP4364798A2 (da)
JP (1) JP2022508648A (da)
KR (1) KR20210125471A (da)
CN (1) CN113490668A (da)
AR (1) AR116687A1 (da)
AU (2) AU2019353144B2 (da)
BR (1) BR112021006488A2 (da)
CA (1) CA3115472A1 (da)
DK (1) DK3860998T3 (da)
EA (1) EA202190952A1 (da)
FI (1) FI3860998T3 (da)
IL (1) IL282021A (da)
MX (1) MX2021003904A (da)
PT (1) PT3860998T (da)
RS (1) RS65335B1 (da)
SG (1) SG11202103451YA (da)
WO (1) WO2020073011A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
CN112724089B (zh) * 2021-01-05 2022-08-26 烟台皓元生物医药科技有限公司 一种2-氨基-3-溴-6-氯吡嗪的合成工艺
WO2023283586A2 (en) * 2021-07-06 2023-01-12 University Of Georgia Research Foundation, Inc. Compositions and methods for treating and preventing viral infections
WO2024099382A1 (en) 2022-11-10 2024-05-16 Annapurna Bio, Inc. Salts and solid forms of a compound having apj receptor activity

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4633956Y1 (da) 1967-06-09 1971-11-24
JPS5959330U (ja) 1982-10-13 1984-04-18 斉藤　晃正 通気性防水部材
JPS614960A (ja) 1984-06-19 1986-01-10 Fuji Photo Film Co Ltd 分析試薬および多層化学分析要素
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
JPH04346987A (ja) 1991-05-23 1992-12-02 Nippon Soda Co Ltd イミダゾピラジン誘導体及びその電子写真感光体としての利用
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
JP3383820B2 (ja) 1993-06-02 2003-03-10 独立行政法人産業技術総合研究所 有機非線形光学材料
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5482960A (en) 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
JPH08157461A (ja) 1994-12-07 1996-06-18 Sankyo Co Ltd スルホン誘導体
IL122427A0 (en) 1995-06-07 1998-06-15 Sugen Inc Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US5751787A (en) 1996-09-05 1998-05-12 Nanoptics, Inc. Materials and methods for improved radiography
ES2215242T3 (es) 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
CA2291647A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU1124399A (en) 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CN1310706A (zh) 1998-02-25 2001-08-29 遗传研究所有限公司 磷脂酶抑制剂
ID26123A (id) 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
JP2002504539A (ja) 1998-02-25 2002-02-12 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
JP2002510623A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 抗糖尿病薬
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AU4981199A (en) 1998-07-08 2000-02-01 Gregory N. Beatch Compositions and methods for modulating sexual activity
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
JP4221129B2 (ja) 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
EP1226136B1 (en) 1999-10-19 2004-12-29 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003512353A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
RU2273642C2 (ru) 1999-12-22 2006-04-10 Метабэйсис Терапьютикс, Инк. Бисамидатные фосфонатные соединения, являющиеся ингибиторами фруктозо-1,6-бисфосфатазы
CZ20022353A3 (cs) 2000-01-07 2003-02-12 Universitaire Instelling Antwerpen Deriváty purinu, způsob jejich přípravy a jejich použití
PT1246808E (pt) 2000-01-14 2011-11-30 Bayer Schering Pharma Ag 1,2¿diarilbenzimidazol para o tratamento de doenças associadas a uma activação das micróglias
CA2402516A1 (en) 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
WO2002009702A2 (en) 2000-07-28 2002-02-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP1311502A1 (en) 2000-08-17 2003-05-21 Celltech R&D Limited Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders
DK1315492T3 (da) 2000-09-06 2008-10-13 Ortho Mcneil Pharm Inc Anvendelse af substituerede pyrazoler til behandling af allergier
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
MXPA03005140A (es) 2000-12-08 2004-10-15 Johnson & Johnson Compuestos de pirrolina sustituidos con indazolilo como inhibidores de cinasa.
US20030109714A1 (en) 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE10135050A1 (de) 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
EP1442028A4 (en) 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7244847B2 (en) 2002-02-06 2007-07-17 Isis Pharmaceuticals, Inc. Benzimidazole compounds
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
NZ535748A (en) 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
AU2003225295A1 (en) 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
US6951881B2 (en) 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
DE60323749D1 (de) 2002-06-05 2008-11-06 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
US20050282733A1 (en) 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
US20040142958A1 (en) 2002-12-13 2004-07-22 Neurogen Corporation Combination therapy for the treatment of pain
WO2004063151A2 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
EP1606266A4 (en) 2003-03-21 2008-06-25 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228268B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
WO2005025579A1 (en) 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005041951A2 (en) 2003-10-28 2005-05-12 Rigel Pharmaceuticals, Inc. Rhodanine derivatives for use as antiviral agents
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US20070054902A1 (en) 2003-12-02 2007-03-08 Shionogi & Co., Ltd. Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
US7791047B2 (en) 2003-12-12 2010-09-07 Semequip, Inc. Method and apparatus for extracting ions from an ion source for use in ion implantation
WO2005065686A1 (en) 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Differentiation modulating agents and uses therefor
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
JP2007533753A (ja) 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
CA2565200C (en) 2004-05-07 2013-12-24 Exelixis, Inc. Raf modulators and methods of use
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
US7569604B2 (en) 2004-06-22 2009-08-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
ES2246721B1 (es) 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
US20100093767A1 (en) 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US20060156486A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
DE102005012872A1 (de) 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102005012873B4 (de) 2005-03-19 2007-05-03 Sanofi-Aventis Deutschland Gmbh Aminocarbonyl substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060229355A1 (en) 2005-04-08 2006-10-12 The Regents Of The University Of California 3.3'-Diindolylmethane compositions inhibit angiogenesis
JP5080450B2 (ja) 2005-04-30 2012-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なピペリジン置換インドール
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
AU2006298164A1 (en) 2005-09-30 2007-04-12 Dainippon Sumitomo Pharma Co., Ltd. Novel fused pyrrole derivative
CN101287707A (zh) 2005-10-13 2008-10-15 德福根有限公司 激酶抑制剂
EP1951315A2 (en) 2005-11-03 2008-08-06 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
CA2634250A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
CN101370775A (zh) 2006-01-13 2009-02-18 惠氏公司 作为5-羟基色胺受体配体的经磺酰基取代1h-吲哚
JP2009523732A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
JP5376956B2 (ja) 2006-02-10 2013-12-25 スムミト コーポレーション ピーエルシー デュシェンヌ型筋ジストロフィーの治療
AU2007224367A1 (en) 2006-03-07 2007-09-13 The Procter & Gamble Company Compositions for oxidatively dyeing keratin fibers and methods for using such compositions
CN101400658A (zh) 2006-03-10 2009-04-01 马林克罗特公司 光活性化合物和组合物及其用途
CN101443001B (zh) 2006-03-20 2013-11-13 西芬克斯医药有限公司 治疗或预防炎性痛的方法
EP2007756B1 (en) 2006-04-07 2015-08-26 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
CA2658959A1 (en) 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
CA2563116A1 (en) 2006-07-06 2008-01-06 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
ES2381215T3 (es) * 2006-10-19 2012-05-24 Signal Pharmaceuticals Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
TW200827340A (en) * 2006-11-10 2008-07-01 Astrazeneca Ab Chemical compounds
US8383662B2 (en) 2006-12-05 2013-02-26 National Chiao Tung University Bicyclic heteroaryl compounds
AU2007329480A1 (en) 2006-12-05 2008-06-12 National Chio Tung University Indazole compounds
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
CN101663279A (zh) 2007-01-19 2010-03-03 阿迪生物科学公司 Mek抑制剂
CN101016294A (zh) 2007-03-13 2007-08-15 中国人民武装警察部队医学院 具有多种生物活性的取代吲哚－3－基草酰胺衍生物
JP2010138072A (ja) 2007-03-29 2010-06-24 Dainippon Sumitomo Pharma Co Ltd 新規な縮合ピロール誘導体
MX2009013753A (es) 2007-06-26 2010-01-26 Sanofi Aventis Una sintesis regioselectiva catalizada por cobre de bencimidazoles y azabencimidazoles.
CN101085779A (zh) 2007-07-11 2007-12-12 中国人民武装警察部队医学院 取代吲哚－3－基草酰表鬼臼毒素衍生物及其盐及其用途
EP2018861A1 (en) 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
ATE495737T1 (de) 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
US8501713B2 (en) 2007-08-03 2013-08-06 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
EP2187883A2 (en) 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
CA2698075C (en) 2007-08-27 2016-04-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
WO2009123776A2 (en) 2008-01-15 2009-10-08 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
PL2307402T3 (pl) 2008-04-29 2013-05-31 Novartis Ag Pochodne imidazo-pirydyny jako inhibitory kinazy podobnej do receptora aktywiny (ALK4 lub ALK5)
US20110039895A1 (en) 2008-04-30 2011-02-17 Glaxo Smith Kline LLC., a corporation Prolyl hydroxylase inhibitors
CA2723279A1 (en) 2008-05-28 2009-12-23 Wyeth Llc 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
WO2010030727A1 (en) 2008-09-10 2010-03-18 Wyeth Llc 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2010051245A1 (en) 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
US9593108B2 (en) 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
WO2010118009A1 (en) 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
EP2416765B1 (en) 2009-04-06 2016-03-30 PTC Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
CA2756568C (en) 2009-04-06 2018-02-13 University Health Network Kinase inhibitors and method of treating cancer with same
BRPI1010514A2 (pt) 2009-04-06 2019-09-24 Ptc Therapeutics Inc derivados de indol e métodos para tratamento antiviral
WO2010117936A1 (en) 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
CA2754702C (en) 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
ES2787599T3 (es) 2009-05-13 2020-10-16 Univ Virginia Patent Foundation Inhibidores de leucemia inv(16)
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
AP2012006094A0 (en) 2009-06-30 2012-02-29 Siga Technologies Inc Treatment and prevention of dengue virus infections.
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
EP2464227A4 (en) 2009-08-10 2013-02-20 Galenea Corp COMPOUNDS AND METHODS OF USE
SG178963A1 (en) 2009-09-03 2012-04-27 Allergan Inc Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
KR101552760B1 (ko) 2009-12-18 2015-09-11 미쓰비시 타나베 파마 코퍼레이션 신규 항혈소판약
US8501770B2 (en) 2009-12-30 2013-08-06 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
JP6152643B2 (ja) 2010-02-22 2017-06-28 株式会社ＡｓｋＡｔ Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用
WO2011116176A1 (en) 2010-03-17 2011-09-22 Sirtris Pharmaceuticals Inc. 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators
PE20130211A1 (es) 2010-04-02 2013-03-22 Senomyx Inc Modificador del sabor dulce
CN103601683B (zh) 2010-04-16 2016-03-30 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
WO2011153310A1 (en) 2010-06-02 2011-12-08 Trius Therapeutics Dihydrofolate reductase inhibitors
WO2012003576A1 (en) * 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012044567A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
WO2012065065A1 (en) 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
DK2669270T3 (da) 2011-01-28 2018-02-26 Sato Pharma Indol-relaterede forbindelser som URAT1-hæmmere
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
WO2012107465A1 (en) 2011-02-09 2012-08-16 F. Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
ES2533042T3 (es) 2011-02-25 2015-04-07 Takeda Pharmaceutical Company Limited Oxazinopteridinas y oxazinopteridinonas N-sustituidas
CN103501610A (zh) 2011-03-09 2014-01-08 西建阿维拉米斯研究公司 Pi3激酶抑制剂和其用途
CN103443080B (zh) 2011-03-16 2016-10-12 田边三菱制药株式会社 具有trpm8拮抗活性的磺酰胺化合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN103608014A (zh) 2011-03-24 2014-02-26 罗楹 激酶抑制剂在治疗和预防炎症疾病中的用途
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
JP5959330B2 (ja) 2011-06-17 2016-08-02 田辺三菱製薬株式会社 新規抗血小板薬
WO2013052395A1 (en) 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
WO2013053045A1 (en) 2011-10-12 2013-04-18 Beta Pharma Canada Inc. Heterocyclic molecules as apoptosis inducers
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
US8785459B2 (en) 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
US20150119402A1 (en) 2012-05-08 2015-04-30 The Regents Of The University Of California Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof
CN104428293B (zh) 2012-06-11 2018-06-08 Ucb生物制药私人有限公司 调节TNFα的苯并咪唑类
AU2013299841B8 (en) 2012-08-07 2017-01-05 Array Biopharma Inc. Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
KR20150058284A (ko) 2012-09-21 2015-05-28 사노피 Apj 수용체 조절자로서의 벤조이미다졸-카르복시산 아미드 유도체
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
AU2013344464A1 (en) 2012-11-16 2015-05-21 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
MX2015013328A (es) 2013-03-19 2016-02-26 Askat Inc Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
JP2016527184A (ja) 2013-05-24 2016-09-08 イオメット ファーマ リミテッド Ｓｌｃ２ａ輸送体阻害剤
BR112016000059B1 (pt) * 2013-07-02 2020-12-29 Syngenta Participations Ag compostos heterociclos bi ou tricíclicos, composição compreendendo os referidos compostos, método para combater e controlar pragas, método para a proteção de material de propagação vegetal do ataque por pragas e material de propagação vegetal revestido com a referida composição
KR20160036053A (ko) 2013-07-31 2016-04-01 메르크 파텐트 게엠베하 Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도
CA2922341C (en) 2013-08-28 2022-06-07 Vanderbilt University Substituted indole mcl-1 inhibitors
CN104447727B (zh) 2013-09-02 2018-04-27 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
MX2020010847A (es) 2014-05-13 2021-07-16 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
CN105732464A (zh) 2014-12-31 2016-07-06 杏国新药股份有限公司 一种规模化生产吲哚化合物的方法
US9809539B2 (en) 2015-03-03 2017-11-07 Shuttle Pharmaceuticals, Llc Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2016176460A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
CA2983314A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
BR112018002763A2 (pt) 2015-08-11 2018-10-09 Connexios Life Sciences Pvt Ltd método para cicatrização de ferimentos
WO2017064068A1 (en) * 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
JP6826116B2 (ja) 2015-11-25 2021-02-03 ユーシービー バイオファルマ エスアールエル プラスメプシンｖ阻害薬としてのイミノテトラヒドロピリミジノン誘導体
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
GB201603104D0 (en) 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
KR102643972B1 (ko) 2016-03-30 2024-03-07 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
SG10201911665UA (en) 2016-04-15 2020-01-30 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
CN109689639B (zh) 2016-07-07 2022-02-18 百时美施贵宝公司 作为rock抑制剂的螺内酰胺
WO2018093579A1 (en) * 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
KR102512190B1 (ko) 2016-12-22 2023-03-21 일루미나 케임브리지 리미티드 쿠마린 화합물 및 형광 표지로서의 이의 용도
EP3573619A4 (en) 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
CN110662544A (zh) 2017-03-24 2020-01-07 纳诺森公司 具有有用的药学应用的稠合三唑并嘧啶化合物
GB201708451D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
KR20200041294A (ko) 2017-06-21 2020-04-21 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
CN109232362B (zh) 2017-07-10 2022-12-27 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
JP7168650B2 (ja) 2017-08-02 2022-11-09 スピノジェニックス， インコーポレイテッド ベンゾチアゾールおよび関連化合物
WO2019032720A1 (en) 2017-08-09 2019-02-14 Sanford Burnham Prebys Medical Discovery Institute APELIN RECEPTOR AGONISTS AND METHODS OF USE
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
WO2019136442A1 (en) 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
WO2019169193A1 (en) 2018-03-01 2019-09-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US20210130312A1 (en) 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2019199979A1 (en) 2018-04-10 2019-10-17 The General Hospital Corporation Antibacterial compounds
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente
CN110835333B (zh) 2018-08-16 2022-10-18 中国药科大学 苯并咪唑取代唑类化合物及其用途
SG11202102367TA (en) 2018-09-18 2021-04-29 Terns Inc Compounds for treating certain leukemias
CN113164454A (zh) 2018-09-28 2021-07-23 奥克塞拉有限公司 Vap-1的抑制剂
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
WO2020146532A1 (en) 2019-01-08 2020-07-16 Sparks Steven Metalloenzyme inhibitor compounds
WO2020160225A1 (en) 2019-01-30 2020-08-06 Ohio State Innovation Foundation ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS
MX2021010701A (es) 2019-03-05 2022-02-21 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad.
EP3946618A1 (en) 2019-04-05 2022-02-09 Storm Therapeutics Ltd Mettl3 inhibitory compounds
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands
US11702404B2 (en) 2019-10-25 2023-07-18 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2021096314A1 (ko) 2019-11-15 2021-05-20 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
US20210300912A1 (en) 2019-12-20 2021-09-30 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
KR20220133271A (ko) 2020-01-29 2022-10-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
WO2021178362A1 (en) 2020-03-03 2021-09-10 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
US20230114408A1 (en) 2020-03-11 2023-04-13 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists

Also Published As

Publication number Publication date
FI3860998T3 (fi) 2024-03-27
IL282021A (en) 2021-05-31
PT3860998T (pt) 2024-04-02
MX2021003904A (es) 2021-10-26
EA202190952A1 (ru) 2021-12-22
TW202028210A (zh) 2020-08-01
JP2022508648A (ja) 2022-01-19
RS65335B1 (sr) 2024-04-30
AU2023254866A1 (en) 2023-11-16
SG11202103451YA (en) 2021-05-28
CN113490668A (zh) 2021-10-08
EP3860998A1 (en) 2021-08-11
US20220125787A1 (en) 2022-04-28
US11471455B2 (en) 2022-10-18
US11944622B2 (en) 2024-04-02
WO2020073011A1 (en) 2020-04-09
EP4364798A2 (en) 2024-05-08
AU2019353144A1 (en) 2021-05-13
CA3115472A1 (en) 2020-04-09
US20230165854A1 (en) 2023-06-01
EP3860998B1 (en) 2023-12-27
KR20210125471A (ko) 2021-10-18
BR112021006488A2 (pt) 2021-07-06
AU2019353144B2 (en) 2023-11-16
AR116687A1 (es) 2021-06-02

Similar Documents

Publication Publication Date Title
DK3658539T3 (da) Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet
DK3860998T3 (da) Forbindelser og sammensætninger til behandlinger af tilstande, der er forbundet med APJ-receptoraktivitet
DK3842442T3 (da) Sammensætninger og fremgangsmåder til hæmning af arginaseaktivitet
DK3660004T3 (da) Forbindelser og fremgangsmåder til målrettet degradering af androgenreceptor
DK3784663T3 (da) Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom
DK3368541T3 (da) Sammensætninger og metoder til inhibiering af arginaseaktivitet
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3484862T3 (da) Forbindelser, sammensætninger og fremgangsmåder til behandling eller forebyggelse af et symptom, der er forbundet med gigt eller hyperurikæmi
DK3250210T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3262008T3 (da) Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3330258T3 (da) 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
DK3253207T3 (da) Fremgangsmåde til desinficering af en overflade og sammensætning, der er egnet til anvendelse dertil
DK3675410T3 (da) Opnåelse og angivelse af komponentkombination, der anvendes til CSI-RS
DK3399985T3 (da) Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer
DK3094178T3 (da) Agrokemisk sammensætning, der omfatter n,n'-diphenyl(thio)urea til forbedring af afgrødeproduktivitet
DK3662925T3 (da) Sammensætning, der omfatter fsh, til behandling af infertilitet
DK3573620T3 (da) Sammensætninger til behandling af hypertension
DK3471722T3 (da) Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
DK3297631T3 (da) NK-1/NK-3-receptorantagonist til behandling af hedeture
DK3480976T3 (da) Tidsjustering til distribueret netværksarkitektur
DK3833434T3 (da) Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf
DK3752283T3 (da) Overlegen kerne-i-skal-komponent-kompositadsorbenter til vsavpsapsa-systemer
DK3728410T3 (da) Fremgangsmåde til behandling af lignocelluloseholdig biomasse
DK3339387T3 (da) Forbindelser på basis af addukter med isocyanater til belægningssammensætninger